Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Change in Receivables (2024 - 2025)

Silence Therapeutics (SLN) has disclosed Change in Receivables for 2 consecutive years, with -$30000.0 as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 104.91% to -$30000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.0 million through Dec 2025, down 213.27% year-over-year, with the annual reading at -$1.0 million for FY2025, 213.27% down from the prior year.
  • Change in Receivables hit -$30000.0 in Q4 2025 for Silence Therapeutics, up from -$62000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $10.0 million in Q1 2024 to a low of -$8.0 million in Q2 2024.